Posted inBiotechnology
Metabolic Reprogramming Boosts Antibiotic Kill Against Resistant Bacteria
In an era where antibiotic resistance has emerged as one of the preeminent global health crises, the battle against multidrug-resistant…
Posted inBiotechnology
Boosting Mitochondria via mitoDREADD-Gs Reverses Cognitive Decline
In the rapidly evolving landscape of neuroscience and cellular biology, the quest to unravel the intricate role of mitochondria in…
Posted inBiotechnology
Fixing Market Failures in Electric Road Investment
In the rapidly evolving landscape of sustainable transportation, electric roads (e-roads) have emerged as a transformative technology poised to revolutionize…
Posted inBiotechnology
Molecular Insights into Theileria Ovis in Sheep, Goats
In a groundbreaking study that addresses the intricate web of parasitic infections in livestock, Dr. F.A. AlFaleh has delivered new…
Posted inBiotechnology
Immune Checkpoint Inhibitor Drug Reactions Revealed
In recent years, immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, offering new hope to patients with various malignancies. These…
Posted inBiotechnology
Enteral Insulin’s Impact on Preterm Infant Microbiota
In a significant stride toward understanding the complex interplay between endocrinology and neonatal microbiology, recent research has delivered compelling insights…
Posted inBiotechnology
Giant “Inocle” Element Boosts Human Oral Microbiome
In a groundbreaking study poised to reshape our understanding of microbial adaptability, researchers have unveiled the discovery of a colossal…
Posted inMedical Technology
SetPoint serves up $140M fundraising after FDA approves its implant for rheumatoid arthritis
Shortly after obtaining a green light from the FDA, SetPoint Medical announced $140 million in new funding to juice the…
Posted inBiotechnology
Expedition inks $645M pact to pocket Fosun’s lung disease asset in knapsack
Young inflammatory disease biotech Expedition Therapeutics is paying $17 million cash for licensing rights to an investigational DPP-1 inhibitor from…
Posted inBiotechnology
Cancer vaccine’s ‘narrow’ phase 3 fail won’t stop IO heading to FDA
IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma trial,…